Cladribine is a B-cell depleting agent approved for the treatment of relapsing forms of multiple sclerosis (MS) in 2019, after it was shown to significantly reduce relapse rates, compared to placebo. To date, its effectiveness compared to other oral disease modifying therapies (DMTs) has not been investigated. Namita Tundia, PhD, EMD Serono Inc., Billerica, MA, discusses the findings of a real-world analysis of the comparative effectiveness and persistence of cladribine and other oral DMTs using data from the MSBase registry. In pairwise comparisons, annualized relapse rate, time-to-first relapse, and time-to-discontinuation were all shown to significantly favor cladribine over other oral DMTs. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.